+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review

1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men's health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa, and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

Eli Lilly and Co Key Recent Developments

  • Apr 17, 2023: Lilly to make record-breaking investment in Indiana manufacturing facilities
  • Apr 13, 2023: Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results
  • Mar 31, 2023: Small and medium biotechs jump on obesity train
  • Mar 06, 2023: Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Eli Lilly and Co - Key Facts
  • Eli Lilly and Co - Key Employees
  • Eli Lilly and Co - Key Employee Biographies
  • Eli Lilly and Co - Major Products and Services
  • Eli Lilly and Co - History
  • Eli Lilly and Co - Company Statement
  • Eli Lilly and Co - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Eli Lilly and Co - Business Description
  • Product Category: Diabetes
  • Overview
  • Performance
  • Product Category: Immunology
  • Overview
  • Performance
  • Product Category: Neuroscience
  • Overview
  • Performance
  • Product Category: Oncology
  • Overview
  • Performance
  • Product Category: Other
  • Overview
  • Performance
  • Geographical Segment: China
  • Capital Expenditure
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: Other Foreign Countries
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Eli Lilly and Co - Corporate Strategy
  • Eli Lilly and Co - SWOT Analysis
  • SWOT Analysis - Overview
  • Eli Lilly and Co - Strengths
  • Eli Lilly and Co - Weaknesses
  • Eli Lilly and Co - Opportunities
  • Eli Lilly and Co - Threats
  • Eli Lilly and Co - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Eli Lilly and Co, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 17, 2023: Lilly to make record-breaking investment in Indiana manufacturing facilities
  • Apr 13, 2023: Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results
  • Mar 31, 2023: Small and medium biotechs jump on obesity train
  • Mar 06, 2023: Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study
  • Mar 03, 2023: Confo and Lilly sign licence deal for peripheral pain candidate
  • Mar 01, 2023: Lilly cuts Insulin prices by 70% and caps patient Insulin Out-of-Pocket costs at $35 per month
  • Feb 13, 2023: Lilly and IABL collaborate to ensure patient access to high-quality affordable insulin in Bangladesh
  • Feb 02, 2023: Lilly reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook
  • Jan 26, 2023: Lilly Supports Direct Relief''s efforts to expand access to medicines by improving cold chain capacity
  • Jan 24, 2023: Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Eli Lilly and Co, Key Facts
  • Eli Lilly and Co, Key Employees
  • Eli Lilly and Co, Key Employee Biographies
  • Eli Lilly and Co, Major Products and Services
  • Eli Lilly and Co, History
  • Eli Lilly and Co, Subsidiaries
  • Eli Lilly and Co, Joint Venture
  • Eli Lilly and Co, Key Competitors
  • Eli Lilly and Co, Ratios based on current share price
  • Eli Lilly and Co, Annual Ratios
  • Eli Lilly and Co, Interim Ratios
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Eli Lilly and Co, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Eli Lilly and Co, Performance Chart (2018 - 2022)
  • Eli Lilly and Co, Ratio Charts
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Novo Nordisk AS
  • Bristol-Myers Squibb Co
  • Biogen Inc
  • F. Hoffmann-La Roche Ltd
  • Kiniksa Pharmaceuticals Ltd
  • Johnson & Johnson
  • Gilead Sciences Inc
  • Sanofi
  • Nymox Pharmaceutical Corp
  • GSK plc
  • Novartis AG
  • Merck & Co Inc
  • AstraZeneca Plc
  • Amgen Inc
  • Takeda Pharmaceutical Co Ltd
  • Heska Corp
  • Pfizer Inc
  • Baxter International Inc
  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc
  • Kiniksa Pharmaceuticals Ltd
  • Baxter International Inc
  • Biogen Inc
  • Sanofi
  • Nymox Pharmaceutical Corp
  • GSK plc
  • Novartis AG
  • Merck & Co Inc
  • AstraZeneca Plc
  • Amgen Inc
  • Heska Corp